Eosinophilic esophagitis market

Eosinophilic Esophagitis Market, by Drug Class (Corticosteroids: Budesonide {Jorveza and Off-label budesonide} and Fluticasone; Proton Pump Inhibitor (PPI): Omeprazole, Esomeprazole, and Others; and Late Stage Pipeline Drugs: Dupixent, APT-1011, Lirentelimab (AK002), Cendakimab, Etrasimod, TAK-721, and Omilancor (BT-11)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2024 - 2031

Request Free Sample

Mar 2024
CMI4909
207 Pages
Excel & Pdf
Pharmaceutical

Summary

Eosinophilic esophagitis (EoE) is a chronic immune system disease of the esophagus. In EoE, a large number of white blood cells called eosinophils are found in the inner lining of the esophagus. This buildup, which is a reaction to food, allergen, or acid reflux, can inflame or injure the esophageal tissue. Difficulties in swallowing, impaction, chest pain often centrally located that does not respond to antacids, and the backflow of undigested food are the signs and symptoms of eosinophilic esophagitis in adults.

Global eosinophilic esophagitis market is estimated to be valued at USD 237.5 Mn in 2024 and is expected to exhibit a CAGR of 33.2% during the forecast period (2024-2031).

Figure 1. Global Eosinophilic Esophagitis Market Value (USD Mn), by Region, 2024

Promising results for potential drug candidates are estimated to drive the global eosinophilic esophagitis market growth during the forecast period.

Drug candidates which are developed and investigated for the treatment of eosinophilic esophagitis have shown promising results in clinical trials. As a result, regulatory authorities such as the U.S. Food and Drug Administration (FDA) are awarding designations to these drug candidates. This is expected to augment the market growth over the forecast period. For instance, in February 2021, Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company, announced that the company received Fast Track designation from the U.S. FDA for the treatment of Eosinophilic Esophagitis (EoE), a rare, chronic allergic inflammatory disease characterized by eosinophilic infiltration of the esophagus.

Eosinophilic Esophagitis Market Report Coverage

Report Coverage	Details
Base Year:	2023	Market Size in 2024:	US$ 237.5 Mn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	33.2%	2031 Value Projection:	US$ 1,767.2 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug Class: Corticosteroids (Budesonide (Jorveza, Off-label budesonide), Fluticasone), Proton Pump Inhibitor (PPI) (Omeprazole, Esomeprazole, Others), Late Stage Pipeline Drugs (Dupixent, APT-1011, Lirentelimab (AK002), Cendakimab, Etrasimod, TAK-721, Omilancor (BT-11) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH
Growth Drivers:	Promising Results for Potential Drug Candidates Increasing Awareness Programs for Eosinophil-associated disorders
Restraints & Challenges:	Stringent Regulations for Drug Approval

Figure 2. Global Eosinophilic Esophagitis Market Share, By Drug Class, 2024

Recent Developments

On February 12, 2024, Takeda Pharmaceutical Company Limited, a multinational pharmaceutical company, announced that the U.S. Food and Drug Administration has approved Eohilia (budesonide oral suspension) for the treatment of eosinophilic esophagitis (EoE) in patients aged 11 years and older. The regulatory move makes Eohilia the first and only approved oral medication for this patient population, and Takeda Pharmaceutical Company Limited expects Eohilia 2 mg/10 mL single-dose stick packs to be available by the end of February 2024.

On January 30, 2024, Revolo Biotherapeutics, a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has given Orphan Drug Designation (ODD) to '1104, a first-in-class immune-resetting peptide being researched as a potential treatment for eosinophilic esophagitis. Revolo submitted its initial request prior to the start of its Phase 2a EoE trial (RVLO 121-04) and revised it following the positive results of an additional Phase 2 study.

On January 25, 2024, Regeneron Pharmaceuticals, Inc., a leading biotechnology company, and Sanofi, a pharmaceutical and healthcare company, announced that the U.S. FDA has approved Dupixent (dupilumab) for the treatment of eosinophilic esophagitis (EoE) in pediatric patients aged 1 to 11 years weighing at least 15 kg. Dupixent is presently the first and only drug approved in the U.S. exclusively for treating these patients.

On January 8, 2024, Calypso Biotech BV, a leader in the development of Interleukin-15 (IL-15) targeted therapies, announced that it has entered into an agreement to be acquired by Novartis AG, a pharmaceutical company. Novartis AG now owns complete rights to CALY-002. Novartis AG plans to further investigate CALY-002 in a wide range of autoimmune diseases with significant unmet medical needs. CALY-002 is now being tested in a Phase 1b trial for patients with Celiac Disease and Eosinophilic Esophagitis.

Increasing awareness programs for Eosinophil-associated disorders is anticipated to propel the global eosinophilic esophagitis market growth over the forecast period.

Various awareness programs have been developed and implemented to educate the public and medical community about eosinophil-associated disorders which is anticipated to drive the market growth over the forecast period. The American Partnership for Eosinophilic Disorders (APFED), a nonprofit organization, was founded in December 2001, which works on educating, raising awareness, supporting, and advocating for patients and families who are suffering from eosinophil-associated diseases.

Global Eosinophilic Esophagitis Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic was first reported on December 31, 2019 in Wuhan, China. The World Health Organization (WHO) declared the COVID-19 a pandemic on March 11, 2020. A number of research have been carried out to depict the relation between the COVID-19 and eosinophilic esophagitis (EoE). Furthermore, research has been underway in which researchers are finding the correlation of mortality in patients due to the COVID-19 and eosinophilic esophagitis.
According to the European Journal of Gastroenterology and Hepatology: December 2020, several studies have been carried out that explain different phenotypes and endotypes of EoE which exist all over the world. Moreover, a subset of EoE is characterized by Th2-predominant inflammation (Th2-high EoE endotype) and positively associated with other allergic diseases such as atopic dermatitis, allergic rhinitis, food allergies, and type-2 high asthma.

Global Eosinophilic Esophagitis Market: Restraints

As of now, no specific treatment has been approved for eosinophilic esophagitis in the U.S. Market players are focusing on developing drug candidates for the treatment of EoE. However, there are many challenges associated with obtaining approval from the regulatory authorities which is anticipated to hinder the market growth over the forecast period. Obtaining approval for the drug from regulatory authorities is a tedious and challenging as regulatory authorities such as the U.S. Food and Drug Administration (FDA) impose substantial and burdensome requirements upon companies involved in the clinical development, manufacturing, marketing, and distribution of drugs

Key Players

Major players operating in the global eosinophilic esophagitis market include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH.

Table of Content

Table of Contents

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global eosinophilic esophagitis market during the forecast period (2024-2031)?

Global elastomeric infusion pumps market size is estimated to be valued at USD 237.5 Mn in 2024 and is expected to exhibit a CAGR of 33.2% between 2024 and 2031.

What are the major factors driving the market growth?

Factors such as increasing awareness programs for Eosinophil-associated disorders are projected to boost the market growth over the forecast period.

Which is the leading drug class segment in the market?

The proton pump inhibitor (PPI) segment is expected to hold a major market share of the market in 2024.

What are the key factors hampering growth of the market?

The major factor hampering the market growth includes stringent regulatory requirements.

Which are the major players operating in the market?

Major players operating in the market include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH.